LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have been given a consensus recommendation of “Moderate Buy” by the seven research firms that are covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $105.80.

Several equities research analysts have weighed in on LMAT shares. Citizens Jmp boosted their price objective on LeMaitre Vascular from $113.00 to $118.00 and gave the stock a “market outperform” rating in a research note on Thursday, February 26th. Weiss Ratings upgraded LeMaitre Vascular from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, March 10th. Wells Fargo & Company boosted their target price on LeMaitre Vascular from $87.00 to $94.00 and gave the company an “equal weight” rating in a research report on Thursday, February 26th. Roth Mkm restated a “buy” rating and set a $117.00 price target (up from $108.00) on shares of LeMaitre Vascular in a report on Thursday, February 26th. Finally, Zacks Research downgraded LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 1st.

LeMaitre Vascular Trading Down 3.4%

Shares of LMAT opened at $106.62 on Friday. The stock has a market capitalization of $2.43 billion, a PE ratio of 42.48, a P/E/G ratio of 3.07 and a beta of 0.66. The company’s fifty day moving average is $96.94 and its 200 day moving average is $90.11. The company has a debt-to-equity ratio of 0.43, a quick ratio of 10.95 and a current ratio of 12.89. LeMaitre Vascular has a fifty-two week low of $71.42 and a fifty-two week high of $115.33.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Wednesday, February 25th. The medical instruments supplier reported $0.68 EPS for the quarter, beating the consensus estimate of $0.67 by $0.01. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 14.72%. The business had revenue of $64.45 million during the quarter, compared to analyst estimates of $62.98 million. During the same quarter last year, the business earned $0.49 earnings per share. LeMaitre Vascular’s quarterly revenue was up 15.7% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. Sell-side analysts expect that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 26th. Stockholders of record on Thursday, March 12th were issued a $0.25 dividend. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.20. The ex-dividend date was Thursday, March 12th. This represents a $1.00 annualized dividend and a dividend yield of 0.9%. LeMaitre Vascular’s dividend payout ratio (DPR) is 39.84%.

Insider Buying and Selling

In related news, CEO George W. Lemaitre sold 150,000 shares of the company’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $106.76, for a total transaction of $16,014,000.00. Following the transaction, the chief executive officer directly owned 1,532,304 shares in the company, valued at approximately $163,588,775.04. This represents a 8.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director David B. Roberts sold 8,464 shares of the firm’s stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $106.80, for a total transaction of $903,955.20. Following the completion of the sale, the director directly owned 17,979 shares of the company’s stock, valued at approximately $1,920,157.20. The trade was a 32.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 215,438 shares of company stock valued at $23,062,911. Company insiders own 9.50% of the company’s stock.

Hedge Funds Weigh In On LeMaitre Vascular

Hedge funds have recently bought and sold shares of the business. Cornerstone Planning Group LLC lifted its position in shares of LeMaitre Vascular by 534.0% during the third quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 283 shares during the last quarter. MAI Capital Management purchased a new position in LeMaitre Vascular in the 3rd quarter worth about $38,000. First Horizon Corp purchased a new position in LeMaitre Vascular in the 3rd quarter worth about $39,000. Geneos Wealth Management Inc. lifted its holdings in LeMaitre Vascular by 250.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after buying an additional 398 shares in the last quarter. Finally, EverSource Wealth Advisors LLC bought a new stake in LeMaitre Vascular during the 2nd quarter valued at about $47,000. Institutional investors own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.